The Implications of Cost-effectiveness Analysis of Medical TechnologyCongress of the United States, Office of Technology Assessment, 1980 - 219 pages |
From inside the book
Results 1-5 of 34
Page 7
... limited approach to analysis , then , seems appropriate for the goal of this assessment . But it does not diminish the need for more complex approaches in research or other specialized circumstances . Applying CEA / CBA in Health Care ...
... limited approach to analysis , then , seems appropriate for the goal of this assessment . But it does not diminish the need for more complex approaches in research or other specialized circumstances . Applying CEA / CBA in Health Care ...
Page 10
... limited experience with making health care allocation decisions based on CEA / CBA , and the expense associated with conducting large numbers of CEA / CBAs required for deci- sionmaking , all support this option . However , if the ...
... limited experience with making health care allocation decisions based on CEA / CBA , and the expense associated with conducting large numbers of CEA / CBAs required for deci- sionmaking , all support this option . However , if the ...
Page 14
... limited ex- periments on the actual formal application of CEA / CBA in program decisionmaking . Three possible areas for the demonstration projects of Option 10 may be medicare's reimbursement coverage decisions , the resource ...
... limited ex- periments on the actual formal application of CEA / CBA in program decisionmaking . Three possible areas for the demonstration projects of Option 10 may be medicare's reimbursement coverage decisions , the resource ...
Page 19
... limited success , re- flecting a lack of resources to implement it effec- tively , political and bureaucratic opposition to it , and unrealistic expectations of its role and potential ( 256 , 352 ) . The formal system did not survive ...
... limited success , re- flecting a lack of resources to implement it effec- tively , political and bureaucratic opposition to it , and unrealistic expectations of its role and potential ( 256 , 352 ) . The formal system did not survive ...
Page 29
... limited approach to the methods seems clearly appropriate and does not diminish the worth of or need for more sophisticated approaches un- der different circumstances . of Psychotherapy , and Background Paper # 5 : Assessment of Four ...
... limited approach to the methods seems clearly appropriate and does not diminish the worth of or need for more sophisticated approaches un- der different circumstances . of Psychotherapy , and Background Paper # 5 : Assessment of Four ...
Other editions - View all
Common terms and phrases
Administration advisory agencies application areas assessment Background Paper biomedical Blue Shield budget Cancer CEA and CBA CEA or CBA CEA/CBA clinical trials conducted considerations Cost of Illness Cost-Benefit Analysis cost-benefit studies cost-effectiveness costs and benefits coverage criteria deci decisionmaking DHHS disease economic economists effectiveness enrollees evaluation example FDA's Federal formal CEA/CBA funding goals gram HCFA Health Care Technology Health Maintenance Organizations health planning health services research hospital HSAs identified impact individual Institute issues measure medical devices medical technologies medicare ment methodological Mishan National NCHCT NCHSR nomic Office option organizations outcomes panel peer review performance physicians policymakers potential priority problem procedures PSRO Public Law quality-adjusted reimbursement safety and efficacy scientific sions social specific staff standards tech techniques tion tive treatment types U.S. Congress
Popular passages
Page 88 - As used in this subsection and subsection (e), the term "substantial evidence" means evidence consisting of adequate and well-controlled investigations, including clinical investigations, by experts qualified by scientific training and experience to evaluate the effectiveness of the drug involved, on the basis of which it could fairly and responsibly be concluded by such experts that the drug will have the effect it purports or is presented to have under the conditions of use prescribed, recommended,...
Page 48 - A), the National Institutes of Health (NIH), and the Food and Drug Administration (FDA).
Page 88 - Administration with respect to such drug, there is lack of substantial evidence consisting of adequate and well-controlled investigations, including clinical investigations, by experts qualified by scientific training and experience to evaluate the effectiveness of the drug involved, on the basis of which it could fairly and responsibly be concluded by such experts that the drug will have the effect it purports or is represented to have under the conditions of use prescribed, recommended, or suggested...
Page 62 - ... (B) the quality of such services meets professionally recognized standards of health care ; and (C) in case such services and items are proposed to be provided in a hospital or other health care facility on an inpatient basis, such services and items could, consistent with the provision of appropriate medical care, be effectively provided on an outpatient basis or more economically in an inpatient health care facility of a different type.
Page 191 - Risk: A measure of the probability of an adverse or untoward outcome and the severity of the resultant harm to health of individuals in a defined population associated with use of a medical technology applied for a given medical problem under specified conditions of use.
Page 47 - Notwithstanding any other provision of this title, no payment may be made under part A or part B for any expenses incurred for items or services — (/) which are not reasonable and necessary for the diagnosis or treatment of illness or injury or to improve the functioning of a malformed body member...
Page 52 - Nothing in this title shall be construed to authorize any Federal officer or employee to exercise any supervision or control over the practice of medicine or the manner in which medical services are provided...
Page 3 - Medical technology: The drugs, devices, and medical and surgical procedures used in medical care, and the organizational and supportive systems within which such care is provided.
Page 190 - Effectiveness: Same as efficacy (see below) except that it refers to average or actual conditions of use. Efficacy: The probability of benefit to individuals in a defined population from a medical technology applied for a given medical problem under ideal conditions of use.
Page 182 - First, cost-benefit analysis as generally understood is only a technique for taking decisions within a framework which has to be decided upon in advance and which involves a wide range of considerations, many of them of a political or social character.